Virios Therapeutics (VIRI) Competitors $2.99 +0.05 (+1.70%) As of 04/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. ORIC, STOK, TRML, ETON, ALLO, TRDA, AMLX, ALT, HRTX, and RGNXShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include ORIC Pharmaceuticals (ORIC), Stoke Therapeutics (STOK), Tourmaline Bio (TRML), Eton Pharmaceuticals (ETON), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Amylyx Pharmaceuticals (AMLX), Altimmune (ALT), Heron Therapeutics (HRTX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. ORIC Pharmaceuticals Stoke Therapeutics Tourmaline Bio Eton Pharmaceuticals Allogene Therapeutics Entrada Therapeutics Amylyx Pharmaceuticals Altimmune Heron Therapeutics REGENXBIO Virios Therapeutics (NASDAQ:VIRI) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings. Does the MarketBeat Community prefer VIRI or ORIC? ORIC Pharmaceuticals received 69 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave ORIC Pharmaceuticals an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% ORIC PharmaceuticalsOutperform Votes7275.00% Underperform Votes2425.00% Do insiders & institutionals have more ownership in VIRI or ORIC? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate VIRI or ORIC? Virios Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 0.33%. ORIC Pharmaceuticals has a consensus price target of $18.86, indicating a potential upside of 301.22%. Given ORIC Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VIRI or ORIC more profitable? ORIC Pharmaceuticals' return on equity of -44.54% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% ORIC Pharmaceuticals N/A -44.54%-40.72% Which has better earnings and valuation, VIRI or ORIC? Virios Therapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-11.07ORIC PharmaceuticalsN/AN/A-$100.70M-$1.82-2.58 Does the media favor VIRI or ORIC? In the previous week, ORIC Pharmaceuticals had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for ORIC Pharmaceuticals and 0 mentions for Virios Therapeutics. ORIC Pharmaceuticals' average media sentiment score of 1.87 beat Virios Therapeutics' score of 0.00 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral ORIC Pharmaceuticals Very Positive Which has more risk and volatility, VIRI or ORIC? Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. SummaryORIC Pharmaceuticals beats Virios Therapeutics on 11 of the 15 factors compared between the two stocks. Remove Ads Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.58M$6.27B$5.29B$7.31BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-11.076.7221.6717.62Price / SalesN/A220.21370.8791.91Price / CashN/A65.6738.1534.64Price / Book14.955.766.363.93Net Income-$5.30M$142.23M$3.20B$247.37M7 Day Performance-17.17%2.89%1.71%0.31%1 Month Performance-51.14%-13.88%-9.47%-7.27%1 Year Performance568.01%-12.34%9.52%-0.56% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$2.99+1.7%$3.00+0.3%+534.8%$57.58MN/A-11.075Gap UpORICORIC Pharmaceuticals3.5122 of 5 stars$4.59-5.9%$18.86+310.8%-47.2%$326.01MN/A-2.5280Gap DownSTOKStoke Therapeutics3.2628 of 5 stars$6.01+1.2%$24.67+310.4%-36.5%$325.01M$36.56M-2.86100Analyst RevisionTRMLTourmaline Bio2.5976 of 5 stars$12.62-1.6%$45.20+258.2%-21.4%$324.15MN/A-4.4844Positive NewsETONEton Pharmaceuticals2.2535 of 5 stars$11.85+0.2%$27.67+133.5%+340.7%$317.79M$39.01M-53.8620Short Interest ↑Gap DownHigh Trading VolumeALLOAllogene Therapeutics2.9534 of 5 stars$1.43-0.7%$9.29+549.6%-58.9%$310.69M$22,000.00-0.92310TRDAEntrada Therapeutics3.1079 of 5 stars$8.19+3.1%$25.67+213.4%-38.9%$307.90M$210.78M5.15110News CoveragePositive NewsAMLXAmylyx Pharmaceuticals2.8601 of 5 stars$3.46+0.9%$8.00+131.2%+87.4%$306.56M$87.37M-0.91200Analyst RevisionNews CoverageALTAltimmune2.6656 of 5 stars$3.98-6.1%$20.83+423.5%-40.0%$306.52M$20,000.00-2.5750Gap DownHRTXHeron Therapeutics3.4891 of 5 stars$1.96-6.7%$5.67+189.1%-34.9%$298.57M$144.29M-10.89300Positive NewsRGNXREGENXBIO4.7094 of 5 stars$5.93-5.7%$32.78+452.7%-63.7%$297.01M$83.33M-1.18370Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies ORIC Pharmaceuticals Alternatives Stoke Therapeutics Alternatives Tourmaline Bio Alternatives Eton Pharmaceuticals Alternatives Allogene Therapeutics Alternatives Entrada Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Altimmune Alternatives Heron Therapeutics Alternatives REGENXBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIRI Stock Free VIRI Stock Alerts